Navigation Links
Glycos Biotechnologies Expands Management Team with Appointment of Vice President of Research and Development
Date:2/2/2010

Successful Industrial Biotechnology Entrepreneur and Researcher Brings Moe Than 20 Years of Experience to Biochemical Innovator

Houston, TX (PRWEB) February 2, 2010 -- Glycos Biotechnologies, Inc. (GlycosBio), an emerging biochemical company pioneering metabolic engineering and microbiology innovations that produce green chemicals, today announced the appointment of Daniel J. Monticello, Ph.D., as Vice President, Research and Development. In this role, Dr. Monticello will be responsible for directing the lab operations for GlycosBio, including research, development and the overall efforts associated with scale-up and commercialization of GlycosBio’s proprietary microbe technology. In addition, Dr. Monticello will be responsible for overseeing GlycosBio’s ongoing demonstration and commercialization efforts in Latin America.

“Dr. Monticello has a unique and broad set of business, management, science and technical skills not only from large, multinational biotechnology organizations but also from the start-up environment,” said Paul Campbell, Ph.D., Chief Science Officer for Glycos Biotechnologies. “His in-depth experience in metabolic engineering as well as industrial fermentations will directly impact and contribute to the ongoing development of GlycosBio’s bioconversion technologies. Dr. Moniticello is a vital addition to our team and will help GlycosBio meet our long-term scientific and business goals.”

Dr. Monticello joins GlycosBio with more than 20 years of experience in industrial biotechnology. Prior to joining GlycosBio, Dr. Monticello was Co-Founder of Molecular LogiX, Inc., an early stage biotechnology company. While at Molecular LogiX, Dr. Monticello was responsible for overseeing the day-to-day operations including finance, strategic planning, science and technology development. Before founding Molecular LogiX, Dr. Monticello was Vice President, Research and Development and Co-Founder for Energy Biosystems Corporation (ENBC). In addition to his entrepreneurial experience, Dr. Monticello held several project and research management positions for Miles, Inc., in both the Biotechnology and Enzyme Products Divisions. Dr. Monticello has contributed to more than 20 issued US patents, is an active presenter in the scientific community and has published dozens of scientific papers and articles.

"Scientific discovery and entrepreneurship have been and continue to be key drivers of my career and GlycosBio embodies both," said Monticello. "GlycosBio has created a truly unique and revolutionary technology that can change the way biofuel, oleochemical, palm oil and petrochemical producers not only create chemicals but also how they manage their business to increase revenue and profitability. GlycosBio is creating better ways to make green chemicals and biofuels to help the industry more efficiently meet its long-term fuel goals. I’m truly excited to be a part of such an innovative and talented team."

About Glycos Biotechnologies, Inc.
Glycos Biotechnologies, Inc. (GlycosBio) is an emerging biochemical company pioneering the metabolic engineering of microbial strains to consume multiple non sugar-based, low value feedstocks for the production of sustainable chemical intermediates and advanced ethanol. By designing differentiated microorganisms, GlycosBio’s bioconversion technology lowers production cost and provides a non food energy balance savings to the chemical and biofuel industries. GlycosBio is privately held with established global relationships focused on product commercialization. For more information, visit www.glycosbio.com.

# # #

Read the full story at http://www.prweb.com/releases/GlycosBio/DanMonticello/prweb3540564.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related biology technology :

1. Glycos Biotechnologies Appoints Chief Executive Officer
2. Glycos Biotechnologies, Inc. Selected to Present at Alternative Energy Innovations 2009
3. Microchip Biotechnologies Raises $18.1M in Series B Financing
4. Epeius Biotechnologies to Partner at BIO Investor Forum
5. Variation Biotechnologies Names Jeff Baxter CEO
6. TriLink BioTechnologies, Inc. Relaunches Oligonucleotide Radiolabeling Services
7. TriLink BioTechnologies to Sponsor GIVING HUNGER THE BLUES, a Benefit Concert to Help Alleviate Hunger in San Diego County
8. Andre Marion Joins Microchip Biotechnologies Board of Directors
9. Solos Endoscopy, Inc. Sells Ovascope and Mastascope Product Line to Lifeline Biotechnologies, Inc.
10. Commonwealth Biotechnologies Presents Data at Forensic Sciences Meeting Confirming Benefits of ZyGEMs DNA Extraction Technology
11. Beginners Luck, or Creative Artists of the First Rank? Epeius Biotechnologies Launches Rexin-G eBook Tutorial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... The Fight Against Cancer Innovation Trust (FACIT) and the ... report that Fusion Pharmaceuticals Inc. (Fusion) has closed a ... – JJDC, Inc. (JJDC) as the lead investor. Additional, ... and Genesys Capital, as well as founding investor FACIT.  ... ...
(Date:2/23/2017)... , Feb. 23, 2017  In Atlanta, it seems ... fashion, and culture intertwine to create an expressive and dynamic ... reflect this energy and contribute to it. ... Hair Fairies seeks to carry on that tradition ... Atlanta salon is the newest of ...
(Date:2/23/2017)... , Feb. 23, 2017  Imanis Life ... product line of oncolytic vaccinia viruses for virotherapy ... as part of Genelux,s proprietary, vaccinia virus-based technology ... excited to enter into a partnership with Genelux ... oncolytic vaccinia viruses for use in research," said ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... that in a published evaluation of multiple immunoassay-based threat detection technologies by ... Energy Laboratory, PathSensors’ CANARY® biosensor threat detection technology was found to have ...
Breaking Biology Technology:
(Date:2/7/2017)... MINNETONKA, Minn. , Feb. 7, 2017   ... that supports the entire spectrum of clinical research, is ... iMedNet , its innovative, highly flexible and ... iMedNet customers. iMedNet is a ... only provides Electronic Data Capture (EDC), but also delivers ...
(Date:2/3/2017)... Feb. 3, 2017 A new independent identity ... Partners, LLP (IdSP) . Designed to fill a critical ... identity market, founding partners Mark Crego and ... years just in identity expertise that span federal governments, ... leadership. The Crego-Kephart combined expertise has a common theme ...
(Date:1/31/2017)... CAMBRIDGE, Mass. , Jan. 31, 2017 /PRNewswire-USNewswire/ ... develop novel therapies for the treatment of bacterial ... generation set of antibacterial candidates from Pro Bono ... the increased prevalence of multi-drug resistant forms of ... by Cantab Anti Infectives Ltd, a PBB group ...
Breaking Biology News(10 mins):